Mobile

A PHASE II, MULTI-CENTER, OPEN-LABEL STUDY OF YM155 IN SUBJECTS WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) PREVIOUSLY TREATED WITH AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003228-20

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of YM155 based on the percentage of subjects that obtain a PSA response. PSA response is defined as a ≥ 50% reduction in PSA that is confirmed by a second PSA value 3 weeks apart. The reference PSA value for these decreases is the baseline PSA value.

Critère d'inclusion

  • Male adults with Hormone Refractory Prostate Cancer who have progressed, as evidenced by PSA progression or progression of measurable disease, after at least 1 prior chemotherapy regimen

Liens